![Kyle Kuvalanka](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kyle Kuvalanka
Profilo
Kyle D.
Kuvalanka is currently an Independent Director at IMV, Inc. since 2021.
Mr. Kuvalanka is Chief Financial Officer & Chief Business Officer at Rome Therapeutics, Inc. starting in 2023.
Mr. Kuvalanka is Chief Financial Officer at Aktis Oncology, Inc. beginning in 2025.
Formerly, Mr. Kuvalanka was Vice President-Strategy & Business Development at Millennium Pharmaceuticals, Inc. from 2012 to 2013.
Mr. Kuvalanka was CFO, Treasurer, CAO & Chief Business Officer at Blueprint Medicines Corp.
from 2013 to 2015.
Mr. Kuvalanka was Chief Operating, Financial & Accounting Officer at Syros Pharmaceuticals, Inc. from 2015 to 2017.
Mr. Kuvalanka held the position of Chief Operating & Financial Officer at Goldfinch Bio, Inc. Education includes an undergraduate degree from Wesleyan University and an MBA from The Wharton School of the University of Pennsylvania.
Posizioni attive di Kyle Kuvalanka
| Società | Posizione | Inizio |
|---|---|---|
| IMV INC. | Direttore/Membro del Consiglio | 01/04/2021 |
| AKTIS ONCOLOGY, INC. | Direttore Finanziario/CFO | 01/11/2025 |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. Develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials | Direttore Finanziario/CFO | 04/10/2023 |
Precedenti posizioni note di Kyle Kuvalanka
| Società | Posizione | Fine |
|---|---|---|
| SYROS PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 22/09/2017 |
| BLUEPRINT MEDICINES CORPORATION | Direttore Finanziario/CFO | 18/09/2015 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures oncology treatment products | Corporate Officer/Principal | 01/09/2013 |
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Develop medicines and therapies for patients with kidney disease | Direttore Finanziario/CFO | - |
Formazione di Kyle Kuvalanka
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 9 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures oncology treatment products | Health Technology |
Wesleyan University
 Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IMV, Inc.
 IMV, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cancer vaccines | Health Technology |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | |
Syros Pharmaceuticals, Inc.
 Syros Pharmaceuticals, Inc. Operates as a therapeutics company focusing on discovering and developing novel gene control therapies | |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Functions as a College/University | |
Goldfinch Bio, Inc.
Goldfinch Bio, Inc. Develop medicines and therapies for patients with kidney disease | |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. Develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials | |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Develops and discovers radiopharmaceuticals to treat tumor cancers |
